SCOTT LAURENCE FRIEDMAN

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. ncbi request reprint Transcriptional regulation of stellate cell activation
    Scott L Friedman
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Gastroenterol Hepatol 21:S79-83. 2006
  2. pmc Mechanisms of hepatic fibrogenesis
    Scott L Friedman
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    Gastroenterology 134:1655-69. 2008
  3. pmc The role of chemokines in acute liver injury
    Yedidya Saiman
    Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine New York, NY, USA
    Front Physiol 3:213. 2012
  4. doi request reprint Therapy for fibrotic diseases: nearing the starting line
    Scott L Friedman
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    Sci Transl Med 5:167sr1. 2013
  5. ncbi request reprint Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1
    Ursula Muñoz
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mol Cancer Res 10:1216-27. 2012
  6. pmc Impaired dermal wound healing in discoidin domain receptor 2-deficient mice associated with defective extracellular matrix remodeling
    Elvira Olaso
    Department of Cell Biology and Histology, University of the Basque Country School of Medicine, Leioa, Spain
    Fibrogenesis Tissue Repair 4:5. 2011
  7. pmc Characterization of the human Activin-A receptor type II-like kinase 1 (ACVRL1) promoter and its regulation by Sp1
    Eva M Garrido-Martin
    Centro de Investigaciones Biologicas, Consejo Superior de Investigaciones Cientificas and Centro de Investigación Biomédica en Red de Enfermedades Raras, Ramiro de Maeztu 9, 28040 Madrid, Spain
    BMC Mol Biol 11:51. 2010
  8. doi request reprint Cannabinoids provoke alcoholic steatosis through a conspiracy of neighbors
    Scott L Friedman
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cell Metab 7:187-8. 2008
  9. pmc Mac the knife? Macrophages- the double-edged sword of hepatic fibrosis
    Scott L Friedman
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Clin Invest 115:29-32. 2005
  10. ncbi request reprint Reversibility of hepatic fibrosis and cirrhosis--is it all hype?
    Scott L Friedman
    Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Nat Clin Pract Gastroenterol Hepatol 4:236-7. 2007

Research Grants

  1. The Role of KLF6 in Hepatic Fibrosis
    Scott Friedman; Fiscal Year: 2009
  2. Role of KLF6 Tumor Suppressor in Hepatocellular Cancer
    Scott Friedman; Fiscal Year: 2007
  3. TRAINING PROGRAM IN INVESTIGATIVE GASTROENTEROLOGY
    Scott Friedman; Fiscal Year: 2007
  4. DDR2 RECEPTOR TYROSINE KINASE IN HEPATIC FIBROSIS
    Scott Friedman; Fiscal Year: 2003
  5. THE ROLE OF STELLATE CELLS IN HEPATIC FIBROSIS
    Scott Friedman; Fiscal Year: 2003
  6. The Role of KLF6 Tumor Suppressor in Hepatocellular Cancer
    Scott Friedman; Fiscal Year: 2009
  7. THE ROLE OF STELLATE CELLS IN HEPATIC FIBROSIS
    Scott Friedman; Fiscal Year: 2001
  8. DDR2 RECEPTOR TYROSINE KINASE IN HEPATIC FIBROSIS
    Scott Friedman; Fiscal Year: 2001
  9. THE ROLE OF STELLATE CELLS IN HEPATIC FIBROSIS
    Scott Friedman; Fiscal Year: 2000
  10. THE ROLE OF STELLATE CELLS IN HEPATIC FIBROSIS
    Scott Friedman; Fiscal Year: 1999

Collaborators

Detail Information

Publications69

  1. ncbi request reprint Transcriptional regulation of stellate cell activation
    Scott L Friedman
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Gastroenterol Hepatol 21:S79-83. 2006
    ....
  2. pmc Mechanisms of hepatic fibrogenesis
    Scott L Friedman
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    Gastroenterology 134:1655-69. 2008
    ..Clinical and translational implications of these advances have become clear, and have begun to impact significantly on the management and outlook of patients with chronic liver disease...
  3. pmc The role of chemokines in acute liver injury
    Yedidya Saiman
    Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine New York, NY, USA
    Front Physiol 3:213. 2012
    ..A better understanding of chemokine/chemokine receptor axes will therefore pave the way for development of novel targeted therapies for the treatment of liver disease...
  4. doi request reprint Therapy for fibrotic diseases: nearing the starting line
    Scott L Friedman
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    Sci Transl Med 5:167sr1. 2013
    ..Together, these advances herald an era of sustained focus on translating the biology of fibrosis into meaningful improvements in quality and length of life in patients with chronic fibrosing diseases...
  5. ncbi request reprint Hepatocyte growth factor enhances alternative splicing of the Kruppel-like factor 6 (KLF6) tumor suppressor to promote growth through SRSF1
    Ursula Muñoz
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mol Cancer Res 10:1216-27. 2012
    ..Enhanced cell replication through increased KLF6 alternative splicing is a novel growth-promoting pathway of HGF that could contribute to the molecule's mitogenic activity in physiologic liver growth and hepatocellular carcinoma...
  6. pmc Impaired dermal wound healing in discoidin domain receptor 2-deficient mice associated with defective extracellular matrix remodeling
    Elvira Olaso
    Department of Cell Biology and Histology, University of the Basque Country School of Medicine, Leioa, Spain
    Fibrogenesis Tissue Repair 4:5. 2011
    ..abstract:..
  7. pmc Characterization of the human Activin-A receptor type II-like kinase 1 (ACVRL1) promoter and its regulation by Sp1
    Eva M Garrido-Martin
    Centro de Investigaciones Biologicas, Consejo Superior de Investigaciones Cientificas and Centro de Investigación Biomédica en Red de Enfermedades Raras, Ramiro de Maeztu 9, 28040 Madrid, Spain
    BMC Mol Biol 11:51. 2010
    ..Here, we have studied the different origins of ACVRL1 transcription, we have analyzed in silico its 5'-proximal promoter sequence and we have characterized the role of Sp1 in the transcriptional regulation of ACVRL1...
  8. doi request reprint Cannabinoids provoke alcoholic steatosis through a conspiracy of neighbors
    Scott L Friedman
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    Cell Metab 7:187-8. 2008
    ....
  9. pmc Mac the knife? Macrophages- the double-edged sword of hepatic fibrosis
    Scott L Friedman
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Clin Invest 115:29-32. 2005
    ..These findings underscore the potential importance of hepatic macrophages in regulating both stellate cell biology and ECM degradation during regression of hepatic fibrosis...
  10. ncbi request reprint Reversibility of hepatic fibrosis and cirrhosis--is it all hype?
    Scott L Friedman
    Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Nat Clin Pract Gastroenterol Hepatol 4:236-7. 2007
  11. ncbi request reprint Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference
    Scott L Friedman
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    Hepatology 45:242-9. 2007
    ....
  12. ncbi request reprint Reversal of hepatic fibrosis -- fact or fantasy?
    Scott L Friedman
    Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Hepatology 43:S82-8. 2006
    ..These advances are sure to be captured in the next 25 years by Hepatology , and to profoundly impact the prognosis of patients with chronic liver disease...
  13. ncbi request reprint Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications
    Scott L Friedman
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    Nat Clin Pract Gastroenterol Hepatol 1:98-105. 2004
    ..We are on the cusp of a new era in which antifibrotic therapies could become important in treating chronic fibrosing liver disease...
  14. doi request reprint Hepatic fibrosis -- overview
    Scott L Friedman
    Division of Liver Diseases, Box 1123, Mount Sinai School of Medicine, 1425 Madison Avenue, Room 11 70C, New York, NY 10029 6574, United States
    Toxicology 254:120-9. 2008
    ....
  15. pmc Genomics and proteomics in liver fibrosis and cirrhosis
    Rebekka A Hannivoort
    Department of Medicine Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    Fibrogenesis Tissue Repair 5:1. 2012
    ..Thus, great opportunities and challenges lie ahead in the field of genomics and proteomics, which, if successful, could transform the diagnosis and treatment of chronic fibrosing liver diseases...
  16. pmc Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis
    Jinsheng Guo
    Division of Liver Diseases, Mount Sinai Hospital, Mount Sinai School of Medicine, New York, NY, USA
    Fibrogenesis Tissue Repair 3:21. 2010
    ..Further clarification of the function and endogenous ligands of TLR4 signaling in HSCs and other liver cells could uncover novel mechanisms of fibrogenesis and facilitate the development of therapeutic strategies...
  17. doi request reprint Evolving challenges in hepatic fibrosis
    Scott L Friedman
    Mount Sinai School of Medicine, Division of Liver Diseases, New York, NY 10029, USA
    Nat Rev Gastroenterol Hepatol 7:425-36. 2010
    ..As a result, focus is shifting towards overcoming key translational challenges in order to accelerate the development of new therapies for patients with chronic liver disease...
  18. ncbi request reprint Liver fibrosis -- from bench to bedside
    Scott L Friedman
    Division of Liver Diseases, PO Box 1123, Mount Sinai School of Medicine, 1425 Madison Ave Room 1170F, New York, NY 10029, USA
    J Hepatol 38:S38-53. 2003
  19. pmc Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene
    Ursula E Lee
    Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    FEBS Lett 584:1006-10. 2010
    ..Whereas KLF6 downregulation by siRNA increased HepG2 proliferation, siRNA to PTTG1 was anti-proliferative. PTTG1 downregulation represents a novel tumor suppressor pathway of KLF6...
  20. pmc KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis
    Goutham Narla
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Clin Invest 118:2711-21. 2008
    ..Together, these findings demonstrate that KLF6-SV1 expression levels in PCa tumors at the time of diagnosis can predict the metastatic behavior of the tumor; thus, KLF-SV1 may represent a novel therapeutic target...
  21. pmc Advances in antifibrotic therapy
    Zahra Ghiassi-Nejad
    Division of Liver Diseases, Box 1123, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    Expert Rev Gastroenterol Hepatol 2:803-16. 2008
    ..Thus, features of injury and stellate cell activation provide a useful template for classifying these emerging agents and point to a new class of therapies for patients with fibrosing liver disease...
  22. ncbi request reprint KLF6 degradation after apoptotic DNA damage
    Michaela S Banck
    Department of Medicine, Division of Hematology Oncology, P O Box 1079, Mount Sinai School of Medicine, One Gustave Levy Place, Room 24 42A, New York, NY 10029, USA
    FEBS Lett 580:6981-6. 2006
    ..KLF6 was unchanged by apoptosis via the extrinsic/death-receptor pathway. Deregulation of KLF6 stability may alter its tumor suppressor function and/or the response of tumors to chemotherapeutics...
  23. ncbi request reprint A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis
    Josep M Llovet
    Mount Sinai Liver Cancer Program, Department of Medicine, Mount Sinai School of Medicine, New York 10029, USA
    Gastroenterology 131:1758-67. 2006
    ..Small liver nodules approximately 2 cm are difficult to characterize by radiologic or pathologic examination. Our aim was to identify a molecular signature to diagnose early hepatocellular carcinoma (HCC)...
  24. pmc Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma
    Steven Yea
    Division of Liver Diseases and Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA
    Gastroenterology 134:1521-31. 2008
    ..The molecular basis for stimulation of KLF6 splicing is unknown...
  25. pmc Adenosine A(2A) receptors play a role in the pathogenesis of hepatic cirrhosis
    Edwin S L Chan
    Division of Clinical Pharmacology, Department of Medicine, New York University School of Medicine, New York, NY 10016, USA
    Br J Pharmacol 148:1144-55. 2006
    ..6. These results demonstrate that hepatic adenosine A(2A) receptors play an active role in the pathogenesis of hepatic fibrosis, and suggest a novel therapeutic target in the treatment and prevention of hepatic cirrhosis...
  26. doi request reprint Scott L. Friedman, 59th President, AASLD
    Meena B Bansal
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    Hepatology 48:1357-8. 2008
  27. pmc Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver
    Scott L Friedman
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    Physiol Rev 88:125-72. 2008
    ..As interest in this cell type intensifies, more surprises and mysteries are sure to unfold that will ultimately benefit our understanding of liver physiology and the diagnosis and treatment of liver disease...
  28. ncbi request reprint Regulation of hepatic stellate cell activation and growth by transcription factor myocyte enhancer factor 2
    Xuemin Wang
    Liver Research Center, Department of Medicine, Rhode Island Hospital and Brown University School of Medicine, Providence 02903, USA
    Gastroenterology 127:1174-88. 2004
    ..Transcriptional regulation plays a key role in this process. We studied the role of transcription factor myocyte enhancer factor 2 (MEF2) during HSC activation...
  29. pmc Interleukin-6 protects hepatocytes from CCl4-mediated necrosis and apoptosis in mice by reducing MMP-2 expression
    Meena B Bansal
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY, USA
    J Hepatol 42:548-56. 2005
    ..Because studies suggest matrix metalloproteinase-2 (MMP-2) may promote liver injury, we examined whether IL-6 exerted its protective effects via regulation of MMP-2...
  30. pmc Krüppel cripples prostate cancer: KLF6 progress and prospects
    Goutham Narla
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York, USA
    Am J Pathol 162:1047-52. 2003
  31. pmc Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation
    Sigal Kremer-Tal
    Division of Liver Diseases and Department of Medicine, Mount Sinai School of Medicine, New York, NY, USA
    J Hepatol 46:645-54. 2007
    ..Hepatocellular carcinoma (HCC) has the most rapidly rising cancer incidence in the US and Europe. The KLF6 tumor suppressor is frequently inactivated in HCC by loss-of-heterozygosity (LOH) and/or mutation...
  32. ncbi request reprint Activation of hepatic stellate cells--a key issue in liver fibrosis
    Helen L Reeves
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Front Biosci 7:d808-26. 2002
    ....
  33. ncbi request reprint Molecular diagnosis of chronic liver disease and hepatocellular carcinoma: the potential of gene expression profiling
    Eric R Lemmer
    Mount Sinai Liver Cancer Program, Division of Liver Disease, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Semin Liver Dis 26:373-84. 2006
    ..Continued progress is anticipated in the practical application of gene array methods to refine diagnosis and therapy of HCC...
  34. ncbi request reprint Cytochrome P450 2E1-derived reactive oxygen species mediate paracrine stimulation of collagen I protein synthesis by hepatic stellate cells
    Natalia Nieto
    Department of Pharmacology and Biological Chemistry, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Biol Chem 277:9853-64. 2002
    ..These co-culture models may be useful for understanding the impact of CYP2E1-derived ROS on stellate cell function and activation...
  35. ncbi request reprint Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma
    Sigal Kremer-Tal
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    Hepatology 40:1047-52. 2004
    ..In conclusion, we propose that KLF6 is deregulated by loss and/or mutation in HCC, and its inactivation may contribute to pathogenesis in a significant number of these tumors...
  36. ncbi request reprint Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination
    Analisa Difeo
    Department of Human Genetics, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, New York 10029, USA
    Clin Cancer Res 12:3730-9. 2006
    ..We investigated the role of the KLF6 tumor suppressor gene and its alternatively spliced isoform KLF6-SV1 in epithelial ovarian cancer (EOC)...
  37. ncbi request reprint Kruppel-like factor 6 (KLF6) is a tumor-suppressor gene frequently inactivated in colorectal cancer
    Helen L Reeves
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    Gastroenterology 126:1090-103. 2004
    ....
  38. pmc A DDX5 S480A polymorphism is associated with increased transcription of fibrogenic genes in hepatic stellate cells
    Jinsheng Guo
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Biol Chem 285:5428-37. 2010
    ..The enhanced fibrogenic activity of the DDX5 risk variant is linked to a reduced repressive function toward these target genes...
  39. ncbi request reprint Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes
    Rifaat Safadi
    Division of Liver Diseases, The Mount Sinai School of Medicine, New York, New York, USA
    Gastroenterology 127:870-82. 2004
    ..Immunomodulatory cytokines, including interleukin-10 (IL-10), may mediate hepatic fibrosis...
  40. pmc Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease
    Hui Hui Tan
    Department of Medicine, The Mount Sinai School of Medicine, New York, NY, USA
    J Immunotoxicol 6:266-75. 2009
    ..050). In conclusion, ambient PM(2.5) exposure may be a significant risk factor for NAFLD progression...
  41. pmc Pivotal role of mTOR signaling in hepatocellular carcinoma
    Augusto Villanueva
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Gastroenterology 135:1972-83, 1983.e1-11. 2008
    ..We evaluated mTOR signaling in human HCC, as well as the antitumoral effect of a dual-level blockade of the mTOR pathway...
  42. pmc Developmental regulation of yolk sac hematopoiesis by Kruppel-like factor 6
    Nobuyuki Matsumoto
    Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, 1425 Madison Ave, Rm 1170F, New York, NY 10029, USA
    Blood 107:1357-65. 2006
    ..Forced expression of KLF6 using a tet-inducible system enhanced the hematopoietic potential of wild-type EBs. Collectively, these findings implicate Klf6 in ES-cell differentiation and hematopoiesis...
  43. pmc Downregulation of hepatic stellate cell activation by retinol and palmitate mediated by adipose differentiation-related protein (ADRP)
    Ting Fang Lee
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Cell Physiol 223:648-57. 2010
    ..Tissue inhibitor of metalloproteinase-1 was not affected. Thus, ADRP upregulation mediated by retinol and palmitate promotes downregulation of HSC activation and is functionally linked to the expression of fibrogenic genes...
  44. ncbi request reprint Hepatic fibrogenesis
    Jinsheng Guo
    Division of Liver Diseases, Mount Sinai Hospital, Mount Sinai School of Medicine, New York, New York 10029, USA
    Semin Liver Dis 27:413-26. 2007
    ....
  45. ncbi request reprint KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma
    Miriam S Teixeira
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Cancer 121:1976-83. 2007
    ..Taken together, these findings suggest that KLF6 LOH represents a clinically-relevant biomarker predicting patient survival and tumor recurrence and that dysregulation of KLF6 function plays an important role in HNSCC progression...
  46. pmc Klf6/copeb is required for hepatic outgrowth in zebrafish and for hepatocyte specification in mouse ES cells
    Xiao Zhao
    Division of Liver Diseases Department of Medicine, Black Family Stem Cell Institute, Mount Sinai School of Medicine, New York, NY 10029, USA
    Dev Biol 344:79-93. 2010
    ..Collectively, these findings indicate that copeb/Klf6 is essential for the development of endoderm-derived organs...
  47. ncbi request reprint Molecular basis of hepatic fibrosis
    Alex Y Hui
    Division of Liver Diseases, Mount Sinai School of Medicine, 1425 Madison Avenue, Room 11 76, New York, NY 10029 6574, USA
    Expert Rev Mol Med 5:1-23. 2003
    ....
  48. ncbi request reprint Genomics and signaling pathways in hepatocellular carcinoma
    Augusto Villanueva
    Mount Sinai Liver Cancer Program, Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA
    Semin Liver Dis 27:55-76. 2007
    ..This review summarizes the most relevant information regarding structural and functional alterations in HCC and describes some of the key signaling pathways implicated in hepatocarcinogenesis...
  49. ncbi request reprint Suppression of glioblastoma tumorigenicity by the Kruppel-like transcription factor KLF6
    Alec C Kimmelman
    The Derald H Ruttenberg Cancer Center, The Mount Sinai School of Medicine, New York, NY 10029, USA
    Oncogene 23:5077-83. 2004
    ..Our results provide the first evidence of functional tumor suppression by KFL6, and its loss may contribute to glial tumor progression...
  50. ncbi request reprint Treatment of hepatic fibrosis: almost there
    Efsevia Albanis
    Division of Liver Diseases, Mount Sinai School of Medicine, Box 1123, 1425 Madison Avenue, Room 1170F, New York, NY 10029 6574, USA
    Curr Gastroenterol Rep 5:48-56. 2003
    ..This review describes the ways in which insights into the cellular basis of hepatic fibrosis are leading to realistic strategies for antifibrotic treatment that may revolutionize the management of patients with chronic liver disease...
  51. pmc Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo
    Pippa Newell
    Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    J Hepatol 51:725-33. 2009
    ..We investigated the molecular alterations of the Ras pathway in HCC and the antineoplastic effects of sorafenib in combination with rapamycin, an inhibitor of mTOR pathway, in experimental models...
  52. pmc Functional role of the KLF6 tumour suppressor gene in gastric cancer
    Jaya Sangodkar
    Department of Medicine, Mount Sinai School of Medicine, New York, NY, United States
    Eur J Cancer 45:666-76. 2009
    ....
  53. ncbi request reprint A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk
    Goutham Narla
    Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA
    Cancer Res 65:1213-22. 2005
    ....
  54. ncbi request reprint Krüppel-like factor-6 promotes preadipocyte differentiation through histone deacetylase 3-dependent repression of DLK1
    Dan Li
    Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Biol Chem 280:26941-52. 2005
    ....
  55. ncbi request reprint Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma
    Olga Camacho-Vanegas
    Department of Genetics and Genomic Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Cancer 121:1390-5. 2007
    ....
  56. ncbi request reprint Diagnosis of hepatic fibrosis in patients with chronic hepatitis C
    Efsevia Albanis
    Division of Liver Diseases, Mount Sinai Medical Center, 1425 Madison Avenue, New York, NY 10029, USA
    Clin Liver Dis 10:821-33. 2006
    ..More accurate and noninvasive methods to diagnose and monitor fibrosis are needed, because these trials will require serial evaluations of liver fibrosis to assess a compound's antifibrotic effect...
  57. pmc Hepatic fibrosis
    Jingjing Jiao
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    Curr Opin Gastroenterol 25:223-9. 2009
    ..This review will summarize the most significant work that contributed to the understanding of liver fibrosis progression and resolution, which in turn has yielded new areas of therapeutic targeting...
  58. ncbi request reprint Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread
    Goutham Narla
    Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Cancer Res 65:5761-8. 2005
    ..Together, these findings begin to highlight a dynamic and functional antagonism between wtKLF6 and its splice variant KLF6 SV1 in tumor growth and dissemination...
  59. ncbi request reprint Prostaglandin E2 inhibits transforming growth factor beta 1-mediated induction of collagen alpha 1(I) in hepatic stellate cells
    Alex Y Hui
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Hepatol 41:251-8. 2004
    ..We assessed the impact of COX-2 inhibition and PGE(2) on the regulation of TGF-beta 1-stimulated matrix synthesis in an immortalized human HSC line, LX-1 and corroborated these findings in primary stellate cells...
  60. ncbi request reprint Cyclin-dependent kinase inhibition by the KLF6 tumor suppressor protein through interaction with cyclin D1
    Sharon Benzeno
    Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Cancer Res 64:3885-91. 2004
    ..Our data suggest that KLF6 converges with the Rb pathway to inhibit cyclin D1/cdk4 activity, resulting in growth suppression...
  61. ncbi request reprint Regulation of Kruppel-like factor 6 tumor suppressor activity by acetylation
    Dan Li
    Department of Human Genetics, Mount Sinai School of Medicine, New York, NY 10029 6574, USA
    Cancer Res 65:9216-25. 2005
    ..These data indicate that acetylation may regulate KLF6 function, and its loss in some tumor-derived mutants could contribute to its failure to suppress growth in prostate cancer...
  62. ncbi request reprint Sex steroids have differential effects on growth and gene expression in primary human prostatic epithelial cell cultures derived from the peripheral versus transition zones
    Alexander Kirschenbaum
    Division of Endocrinology, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA
    Carcinogenesis 27:216-24. 2006
    ..Finally, we demonstrate divergent responses to sex hormones in the two basal cell populations. The gene expression pattern in the PZ cells may partially explain the predominance of prostate cancer development in this region...
  63. doi request reprint Pathogenesis of liver fibrosis
    Virginia Hernandez-Gea
    Mount Sinai School of Medicine, New York, New York 10029, USA
    Annu Rev Pathol 6:425-56. 2011
    ..As pathways of fibrogenesis are increasingly clarified, the key challenge will be translating new advances into the development of antifibrotic therapies for patients with chronic liver disease...
  64. ncbi request reprint Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2
    Elvira Olaso
    Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Biol Chem 277:3606-13. 2002
    ..These data establish a role for DDR2 in critical events during wound repair...
  65. ncbi request reprint Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen
    Kazuo Ikeda
    Department of Medicine, Division of Liver Diseases, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Biol Chem 277:19206-12. 2002
    ..The data support a model in which Src and the DDR2 receptor cooperate in a regulated fashion to direct the phosphorylation of both the receptor and its targets...
  66. ncbi request reprint Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species
    Natalia Nieto
    Department of Biochemistry, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Hepatology 35:62-73. 2002
    ..Thus, besides perturbing the homeostasis of hepatocytes, CYP2E1-derived diffusible oxidants may also interact with stellate cells and contribute to hepatic fibrosis...
  67. ncbi request reprint Enhanced oral tolerance in transgenic mice with hepatocyte secretion of IL-10
    Rifaat Safadi
    Division of Liver Diseases, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Immunol 175:3577-83. 2005
    ..In contrast to hepatic TG expression of rIL-10, systemic administration of rIL-10 had only a modest effect on tolerance. IL-10, when transgenically expressed in the liver enhances mucosal tolerance to an oral Ag...
  68. ncbi request reprint The answer: angiotensin II. The question: what do inflammation, oxidant stress and fibrogenesis have in common?
    Scott L Friedman
    Mount Sinai School of Medicine, Box 1123, 1425 Madison Ave, Room 11 70F, New York, NY 10029, USA
    J Hepatol 40:1050-2. 2004
  69. pmc Experimental models of hepatocellular carcinoma
    Philippa Newell
    Division of Liver Diseases, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, NY 10029, USA
    J Hepatol 48:858-79. 2008
    ..These models will be instrumental in the evaluation of compounds targeting specific molecular pathways in future preclinical studies...

Research Grants24

  1. The Role of KLF6 in Hepatic Fibrosis
    Scott Friedman; Fiscal Year: 2009
    ..These innovative studies could lead to new insights into stellate cell activation that may offer novel approaches to treating hepatic fibrosis, for which there are currently no effective therapies. ..
  2. Role of KLF6 Tumor Suppressor in Hepatocellular Cancer
    Scott Friedman; Fiscal Year: 2007
    ..abstract_text> ..
  3. TRAINING PROGRAM IN INVESTIGATIVE GASTROENTEROLOGY
    Scott Friedman; Fiscal Year: 2007
    ....
  4. DDR2 RECEPTOR TYROSINE KINASE IN HEPATIC FIBROSIS
    Scott Friedman; Fiscal Year: 2003
    ..The findings could lead to new treatments for this debilitating and incurable condition. ..
  5. THE ROLE OF STELLATE CELLS IN HEPATIC FIBROSIS
    Scott Friedman; Fiscal Year: 2003
    ..The findings could lead to new treatments for this debilitating and incurable condition. ..
  6. The Role of KLF6 Tumor Suppressor in Hepatocellular Cancer
    Scott Friedman; Fiscal Year: 2009
    ..abstract_text> ..
  7. THE ROLE OF STELLATE CELLS IN HEPATIC FIBROSIS
    Scott Friedman; Fiscal Year: 2001
    ..The findings could lead to new treatments for this debilitating and incurable condition. ..
  8. DDR2 RECEPTOR TYROSINE KINASE IN HEPATIC FIBROSIS
    Scott Friedman; Fiscal Year: 2001
    ..The findings could lead to new treatments for this debilitating and incurable condition. ..
  9. THE ROLE OF STELLATE CELLS IN HEPATIC FIBROSIS
    Scott Friedman; Fiscal Year: 2000
    ..The findings could lead to new treatments for this debilitating and incurable condition. ..
  10. THE ROLE OF STELLATE CELLS IN HEPATIC FIBROSIS
    Scott Friedman; Fiscal Year: 1999
    ..The findings could lead to new treatments for this debilitating and incurable condition. ..
  11. The Role of KLF6 in Hepatic Fibrosis
    Scott Friedman; Fiscal Year: 2006
    ..These innovative studies could lead to new insights into stellate cell activation that may offer novel approaches to treating hepatic fibrosis, for which there are currently no effective therapies. ..
  12. Role of KLF6 Tumor Suppressor in Hepatocellular Cancer
    Scott Friedman; Fiscal Year: 2006
    ..abstract_text> ..
  13. Role of KLF6 Tumor Suppressor in Hepatocellular Cancer
    Scott Friedman; Fiscal Year: 2005
    ..abstract_text> ..
  14. Role of KLF6 Tumor Suppressor in Hepatocellular Cancer
    Scott Friedman; Fiscal Year: 2004
    ..abstract_text> ..
  15. DDR2 RECEPTOR TYROSINE KINASE IN HEPATIC FIBROSIS
    Scott Friedman; Fiscal Year: 2004
    ..The findings could lead to new treatments for this debilitating and incurable condition. ..
  16. THE ROLE OF STELLATE CELLS IN HEPATIC FIBROSIS
    Scott Friedman; Fiscal Year: 2002
    ..The findings could lead to new treatments for this debilitating and incurable condition. ..
  17. The Role of KLF6 in Hepatic Fibrosis
    Scott Friedman; Fiscal Year: 2007
    ..These innovative studies could lead to new insights into stellate cell activation that may offer novel approaches to treating hepatic fibrosis, for which there are currently no effective therapies. ..
  18. DDR2 RECEPTOR TYROSINE KINASE IN HEPATIC FIBROSIS
    Scott Friedman; Fiscal Year: 2002
    ..The findings could lead to new treatments for this debilitating and incurable condition. ..
  19. The Role of KLF6 in Hepatic Fibrosis
    Scott Friedman; Fiscal Year: 2005
    ..These innovative studies could lead to new insights into stellate cell activation that may offer novel approaches to treating hepatic fibrosis, for which there are currently no effective therapies. ..
  20. The Role of KLF6 Tumor Suppressor in Hepatocellular Cancer
    SCOTT LAURENCE FRIEDMAN; Fiscal Year: 2010
    ..abstract_text> ..